In 2018, Neuren partnered with ACADIA Pharmaceuticals, securing an upfront payment of US$100 million. ACADIA handles ...
Morningstar says mining M&A to pick up; Neuren’s Daybue eyes $US700m global sales; building approvals surge in November; job ...
Acadia Pharmaceuticals, partner of Neuren Pharmaceuticals, anticipates global net sales of its Rett syndrome treatment, ...
Neuren Pharmaceuticals (ASX: NEU) today shared highlights from partner Acadia Pharmaceuticals' presentation at the J.P.
Biotech company Neuren Pharmaceuticals has said projected global sales of its Rett syndrome treatment Daybue are set to reach ...
SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...
A CONNECTION between an East Lothian business and a charity researching a rare neurological condition has reached a fundraising milestone.
Coleen Rooney returned to reality on Tuesday as she went on a big food shop at her local Waitrose . The I'm A Celebrity star, ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback